Company: VRCA
Filing Date: 2025-03-11
Form Type: S-3
Source: 0001193125-25-052031
Chunk: 4

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-03-11
Form: S-3
Chunk 4
---
 THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The date of this prospectus is , 2025.

TABLE OF CONTENTS

|                                                   |     | Page |    |
| ABOUT THIS PROSPECTUS                             |     |      |  i |
| SUMMARY                                           |     |      |  1 |
| RISK FACTORS                                      |     |      |  6 |
| SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS |     |      |  7 |
| USE OF PROCEEDS                                   |     |      |  9 |
| DESCRIPTION OF CAPITAL STOCK                      |     |      | 10 |
| DESCRIPTION OF DEBT SECURITIES                    |     |      | 14 |
| DESCRIPTION OF WARRANTS                           |     |      | 21 |
| LEGAL OWNERSHIP OF SECURITIES                     |     |      | 24 |
| PLAN OF DISTRIBUTION                              |     |      | 28 |
| LEGAL MATTERS                                     |     |      | 30 |
| EXPERTS                                           |     |      | 30 |
| WHERE YOU CAN FIND MORE INFORMATION               |     |      | 30 |
| INCORPORATION OF CERTAIN INFORMATION BY REFERENCE |     |      | 31 |

ABOUT THIS PROSPECTUS

This prospectus is a part of a registration statement on Form S-3 that we filed with the Securities and Exchange
Commission, or SEC, utilizing a “shelf” registration process. Under this shelf registration statement, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings up to a total
aggregate offering price of $150,000,000. This prospectus provides you with a general description of the securities we may offer.

Each time we sell
securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain
material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any
documents that